Biolase Debt to Equity Ratio 2010-2024 | BIOL

Current and historical debt to equity ratio values for Biolase (BIOL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biolase debt/equity for the three months ending March 31, 2024 was 34.06.
Biolase Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-03-31 $0.03B $0.00B 126.71
2023-12-31 $0.03B $0.00B 16.95
2023-09-30 $0.03B $0.01B 5.59
2023-06-30 $0.03B $0.01B 4.40
2023-03-31 $0.03B $0.01B 4.14
2022-12-31 $0.03B $0.01B 6.81
2022-09-30 $0.03B $0.01B 2.09
2022-06-30 $0.03B $0.02B 1.35
2022-03-31 $0.03B $0.02B 1.44
2021-12-31 $0.03B $0.03B 1.19
2021-09-30 $0.03B $0.03B 0.93
2021-06-30 $0.03B $0.03B 0.84
2021-03-31 $0.03B $0.03B 0.89
2020-12-31 $0.03B $0.01B 3.09
2020-09-30 $0.03B $0.01B 2.03
2020-06-30 $0.03B $0.00B 20.20
2020-03-31 $0.03B $-0.00B -28.53
2019-12-31 $0.03B $0.00B 6.34
2019-09-30 $0.03B $-0.00B -27.52
2019-06-30 $0.03B $0.00B 7.53
2019-03-31 $0.03B $0.01B 3.85
2018-12-31 $0.03B $0.01B 2.47
2018-09-30 $0.02B $0.02B 1.10
2018-06-30 $0.02B $0.02B 0.75
2018-03-31 $0.02B $0.03B 0.62
2017-12-31 $0.01B $0.03B 0.47
2017-09-30 $0.02B $0.02B 0.77
2017-06-30 $0.02B $0.03B 0.67
2017-03-31 $0.02B $0.02B 1.02
2016-12-31 $0.02B $0.02B 0.90
2016-09-30 $0.02B $0.03B 0.71
2016-06-30 $0.02B $0.02B 0.90
2016-03-31 $0.02B $0.02B 0.78
2015-12-31 $0.02B $0.03B 0.70
2015-09-30 $0.02B $0.03B 0.79
2015-06-30 $0.02B $0.03B 0.65
2015-03-31 $0.02B $0.04B 0.47
2014-12-31 $0.02B $0.04B 0.41
2014-09-30 $0.02B $0.01B 1.69
2014-06-30 $0.02B $0.00B 8.09
2014-03-31 $0.02B $0.01B 2.18
2013-12-31 $0.02B $0.01B 2.66
2013-09-30 $0.02B $0.01B 2.46
2013-06-30 $0.02B $0.01B 2.98
2013-03-31 $0.02B $0.01B 2.15
2012-12-31 $0.02B $0.01B 1.71
2012-09-30 $0.02B $0.01B 1.79
2012-06-30 $0.02B $0.01B 1.66
2012-03-31 $0.02B $0.01B 1.34
2011-12-31 $0.02B $0.01B 1.37
2011-09-30 $0.02B $0.01B 1.06
2011-06-30 $0.02B $0.02B 1.01
2011-03-31 $0.02B $0.00B 3.68
2010-12-31 $0.02B $-0.00B -6.96
2010-09-30 $0.02B $-0.00B -6.50
2010-06-30 $0.02B $-0.00B -16.56
2010-03-31 $0.02B $0.00B 6.19
2009-12-31 $0.01B $0.01B 1.80
2009-09-30 $0.01B $0.01B 1.54
2009-06-30 $0.02B $0.01B 1.90
2009-03-31 $0.02B $0.01B 3.50
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.006B $0.049B
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $72.887B 20.45
Becton Dickinson (BDX) United States $66.122B 18.71
West Pharmaceutical Services (WST) United States $24.159B 43.30
Cardinal Health (CAH) United States $23.477B 13.43
Align Technology (ALGN) United States $19.244B 37.15
Cooper (COO) United States $18.860B 28.54
Labcorp (LH) United States $16.830B 14.49
Henry Schein (HSIC) United States $9.184B 16.34
DENTSPLY SIRONA (XRAY) United States $5.702B 14.76
Merit Medical Systems (MMSI) United States $4.760B 26.09
CONMED (CNMD) United States $2.281B 20.69
Patterson (PDCO) United States $2.145B 10.27
STAAR Surgical (STAA) United States $2.022B 77.66
Atrion (ATRI) United States $0.815B 43.51
Lifevantage (LFVN) United States $0.096B 12.34
Pro-Dex (PDEX) United States $0.067B 34.03